p53 as a hub in cellular redox regulation and therapeutic target in cancer
Open accessThe DOI matches its Crossref record; 130 of the 132 references it cites were found in a registry or an index.
Abstract
The TP53 tumor suppressor gene encodes a DNA-binding transcription factor that regulates multiple cellular processes including cell growth and cell death. The ability of p53 to bind to DNA and activate transcription is tightly regulated by post-translational modifications and is dependent on a reducing cellular environment. Some p53 transcriptional target genes are involved in regulation of the cellular redox homeostasis, e.g. TIGAR and GLS2. A large fraction of human tumors carry TP53 mutations, most commonly missense mutations that lead to single amino acid substitutions in the core domain. Mutant p53 proteins can acquire so called gain-of-function activities and influence the cellular redox balance in various ways, for instance by binding of the Nrf2 transcription factor, a major regulator of cellular redox state. The DNA-binding core domain of p53 has 10 cysteine residues, three of which participate in holding a zinc atom that is critical for p53 structure and function. Several novel compounds that refold and reactivate missense mutant p53 bind to specific p53 cysteine residues. These compounds can also react with other thiols and target components of the cellular redox system, such as glutathione. Dual targeting of mutant p53 and redox homeostasis may allow more efficient treatment of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is established that transcription factor p53 is the master regulator of the DNA damage response and is stabilized and transactivated in response to DNA damage [ 38 , 39 , 40 , 41 ].”
From Differential Induction of Reactive Oxygen Species and Expression of Antioxidant Enzymes in Human Melanocytes Correlate with Melanin Content: Implications on the Response to Solar UV and Melanoma Susceptibility (2022) · cites this paper as [40]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
MicroRNA-124 Regulates the Proliferation of Colorectal Cancer Cells by TargetingiASPP
Liu, K., Zhao, H., Yao, H., Lei, S., Lei, Z., Li, T., & Qi, H. (2013) · BioMed Research International · doi:10.1155/2013/867537 · Cited by 60
RetractedUnderstanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease
Stockwell, B. R., Friedmann Angeli, J. P., Bayir, H., Bush, A. I., Conrad, M., Dixon, S. J., Fulda, S., Gascón, S., Hatzios, S. K., Kagan, V. E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.021 · Cited by 7,695 · cited 16×
“FDXR is a mitochondrial protein involved in iron–sulfur cluster formation and the transfer of electrons from NADPH to cytochrome P450 enzymes.”
BackgroundInfluentialFree radicals, metals and antioxidants in oxidative stress-induced cancer
Valko, M., Rhodes, C. J., Moncol, J., Izakovic, M., & Mazur, M. (2006) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2005.12.009 · Cited by 6,680 · cited 1×
“Counteracting oxidative stress in order to maintain a reduced environment is essential as accumulation of oxygen species is harmful to the cell and can initiate cancer (Valko et al., 2006).”
BackgroundMutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
Ferroptosis as a p53-mediated activity during tumour suppression
Jiang, L., Kon, N., Li, T., Wang, S.-J., Su, T., Hibshoosh, H., Baer, R., & Gu, W. (2015) · Nature · doi:10.1038/nature14344 · Cited by 3,398 · cited 11×
“As SLC7A11 controls both cystine/cysteine redox cycling and the availability GSH building blocks, the repression of SLC7A11 renders mutant p53 cells more sensitive to oxidative assaults.”
BackgroundInfluentialBlinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 1×
“Also, p53 has continued to fascinate and surprise investigators through its involvement in a wide range of diverse cellular processes (Vousden and Prives, 2009), and by the discovery of multiple p53 isoforms with as yet poorly understood functions (Marcel et al.”
BackgroundWendel, A. (1981) · Methods in Enzymology · doi:10.1016/s0076-6879(81)77046-0 · Cited by 3,009
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551 · cited 1×
“Thus, as mutant p53 prolongs TNF-α-induced NFκB signaling (Cooks et al., 2013), it is conceivable that mutant p53 can upregulate Nrf2 via NFκB.”
BackgroundA model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277 · cited 1×
“Similarly, oncogenes such as Kras, Braf, and Myc can promote increased transcription of Nrf2 and its antioxidant downstream targets, which might lead to a more reduced cellular milieu (DeNicola et al., 2011).”
BackgroundAntioxidants Maintain Cellular Redox Homeostasis by Elimination of Reactive Oxygen Species
He, L., He, T., Farrar, S., Ji, L., Liu, T., & Ma, X. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485089 · Cited by 2,127
Cellular mechanisms and physiological consequences of redox-dependent signalling
Holmström, K. M., & Finkel, T. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3801 · Cited by 2,093
Glutaminolysis and transferrin regulate ferroptosis
Gao, M., Monian, P., Quadri, N., Ramasamy, R., & Jiang, X. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.06.011 · Cited by 2,069 · cited 6×
“, 2016) and GLS2 (Gao et al., 2015), and negative regulation of SLC7A11 (Jiang et al.”
BackgroundInfluentialBrigelius-Flohé, R., & Maiorino, M. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.11.020 · Cited by 1,904 · cited 1×
“The tripeptide glutathione or L-γ-glutamyl-L-cysteinyl-glycine (GSH) reacts with electrophilic and oxidizing species and is utilized as a cofactor and electron donor by glutathione S-transferases (GST), glutaredoxins (Grx1–5) and glutathione peroxidases (GPx1–8) (Brigelius-Flohe and Maiorino, 2013).”
BackgroundNRF2 and the Hallmarks of Cancer
Rojo de la Vega, M., Chapman, E., & Zhang, D. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.022 · Cited by 1,672
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132 · cited 2×
“Mutant p53 may also acquire novel so called gain-of-function activities (GOFs), such as binding to other cellular proteins and promiscuous transcriptional transactivation (Brosh and Rotter, 2009; Sabapathy and Lane, 2018).”
BackgroundThe antioxidant function of the p53 tumor suppressor
Sablina, A. A., Budanov, A. V., Ilyinskaya, G. V., Agapova, L. S., Kravchenko, J. E., & Chumakov, P. M. (2005) · Nature Medicine · doi:10.1038/nm1320 · Cited by 1,121
Ramos-Gomez, M., Kwak, M.-K., Dolan, P. M., Itoh, K., Yamamoto, M., Talalay, P., & Kensler, T. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051618798 · Cited by 1,102
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 14×
“Thiol-reactive compounds such as PK11007 and MQ (APR-246) not only reactivate mutant p53 but target cellular antioxidant components such as TrxR and GSH as well, leading to oxidative stress (Figure 4).”
BackgroundSelf-citationSerine starvation induces stress and p53-dependent metabolic remodelling in cancer cells
Maddocks, O. D. K., Berkers, C. R., Mason, S. M., Zheng, L., Blyth, K., Gottlieb, E., & Vousden, K. H. (2013) · Nature · doi:10.1038/nature11743 · Cited by 1,007
Lewerenz, J., Hewett, S. J., Huang, Y., Lambros, M., Gout, P. W., Kalivas, P. W., Massie, A., Smolders, I., Methner, A., Pergande, M., et al. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4391 · Cited by 978
Census and evaluation of p53 target genes
Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971
The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity
Xie, Y., Zhu, S., Song, X., Sun, X., Fan, Y., Liu, J., Zhong, M., Yuan, H., Zhang, L., Billiar, T. R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.055 · Cited by 952
Koppula, P., Zhang, Y., Zhuang, L., & Gan, B. (2018) · Cancer Communications · doi:10.1186/s40880-018-0288-x · Cited by 915
Targeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889 · cited 3×
“PK083, ZMC1, PK7088, stictic acid, and KSS-9, have been identified by rational design, database analysis and/or molecular modeling (Bykov et al., 2018).”
BackgroundSelf-citationAntioxidants Accelerate Lung Cancer Progression in Mice
Sayin, V. I., Ibrahim, M. X., Larsson, E., Nilsson, J. A., Lindahl, P., & Bergo, M. O. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007653 · Cited by 867
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865
Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function
Hu, W., Zhang, C., Wu, R., Sun, Y., Levine, A., & Feng, Z. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001006107 · Cited by 862
Pharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 799
p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase
Jiang, P., Du, W., Wang, X., Mancuso, A., Gao, X., Wu, M., & Yang, X. (2011) · Nature Cell Biology · doi:10.1038/ncb2172 · Cited by 795
Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses
Ou, Y., Wang, S.-J., Li, D., Chu, B., & Gu, W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607152113 · Cited by 765
Suzuki, S., Tanaka, T., Poyurovsky, M. V., Nagano, H., Mayama, T., Ohkubo, S., Lokshin, M., Hosokawa, H., Nakayama, T., Suzuki, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002459107 · Cited by 705
GPx4, Lipid Peroxidation, and Cell Death: Discoveries, Rediscoveries, and Open Issues
Maiorino, M., Conrad, M., & Ursini, F. (2018) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7115 · Cited by 703
Direct Interaction between Nrf2 and p21Cip1/WAF1 Upregulates the Nrf2-Mediated Antioxidant Response
Chen, W., Sun, Z., Wang, X.-J., Jiang, T., Huang, Z., Fang, D., & Zhang, D. D. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.04.029 · Cited by 638 · cited 4×
“…et al., 2014), Sestrins 1 and 2 (SESN1/2) (Bae et al., 2013), tumor protein p53-induced nuclear protein 1 (TP53INP1) (Cano et al., 2009), and p21 (Chen et al., 2009). p53induced TIGAR inhibits glycolysis and enhances PPP flux, resulting in more intracellular NADPH reductive power (Lee et al.,…”
BackgroundInfluentialPRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Self-citationRescuing the function of mutant p53
Bullock, A. N., & Fersht, A. R. (2001) · Nature Reviews Cancer · doi:10.1038/35094077 · Cited by 568
p53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells
Tarangelo, A., Magtanong, L., Bieging-Rolett, K. T., Li, Y., Ye, J., Attardi, L. D., & Dixon, S. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.077 · Cited by 554
The BCL-2 arbiters of apoptosis and their growing role as cancer targets
Adams, J. M., & Cory, S. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.161 · Cited by 530
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
Bae, S. H., Sung, S. H., Oh, S. Y., Lim, J. M., Lee, S. K., Park, Y. N., Lee, H. E., Kang, D., & Rhee, S. G. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2012.12.002 · Cited by 492 · cited 7×
“…production of GSH through several target genes and pathways, e.g. TIGAR (Lee et al., 2014), GLS2 (Hu et al., 2010; Suzuki et al., 2010), SESN1/2 (Bae et al., 2013), and p21-dependent activation of Nrf2. p53 downregulation increases DNA oxidation and oxygen species formation (Sablina et al.,…”
BackgroundInfluentialIdentification of redox/repair protein Ref-1 as a potent activator of p53.
Jayaraman, L., Murthy, K. G., Zhu, C., Curran, T., Xanthoudakis, S., & Prives, C. (1997) · Genes & Development · doi:10.1101/gad.11.5.558 · Cited by 481
Antioxidant response elements: Discovery, classes, regulation and potential applications
Raghunath, A., Sundarraj, K., Nagarajan, R., Arfuso, F., Bian, J., Kumar, A. P., Sethi, G., & Perumal, E. (2018) · Redox Biology · doi:10.1016/j.redox.2018.05.002 · Cited by 468
Cooks, T., Pateras, I. S., Tarcic, O., Solomon, H., Schetter, A. J., Wilder, S., Lozano, G., Pikarsky, E., Forshew, T., Rozenfeld, N., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.022 · Cited by 466
Acetylation Is Crucial for p53-Mediated Ferroptosis and Tumor Suppression
Wang, S.-J., Li, D., Ou, Y., Jiang, L., Chen, Y., Zhao, Y., & Gu, W. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.022 · Cited by 462
Hayano, M., Yang, W. S., Corn, C. K., Pagano, N. C., & Stockwell, B. R. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.93 · Cited by 457
Thioredoxin-dependent Redox Regulation of p53-mediated p21 Activation
Ueno, M., Masutani, H., Arai, R. J., Yamauchi, A., Hirota, K., Sakai, T., Inamoto, T., Yamaoka, Y., Yodoi, J., & Nikaido, T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.50.35809 · Cited by 428
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
Wang, W., Kryczek, I., Dostál, L., Lin, H., Tan, L., Zhao, L., Lu, F., Wei, S., Maj, T., Peng, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.009 · Cited by 422
Redox modulation of p53 conformation and sequence-specific DNA binding in vitro.
Hainaut, P. L., & Milner, J. (1993) · PubMed · Cited by 404
Thioredoxin/Txnip: Redoxisome, as a Redox Switch for the Pathogenesis of Diseases
Yoshihara, E., Masaki, S., Matsuo, Y., Chen, Z., Tian, H., & Yodoi, J. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00514 · Cited by 362
Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia
Zhang, W., Trachootham, D., Liu, J., Chen, G., Pelicano, H., Garcia-Prieto, C., Lu, W., Burger, J. A., Croce, C. M., Plunkett, W., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2432 · Cited by 357
p53 Suppresses the Nrf2-dependent Transcription of Antioxidant Response Genes
Faraonio, R., Vergara, P., Di Marzo, D., Pierantoni, M. G., Napolitano, M., Russo, T., & Cimino, F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605707200 · Cited by 349
Jeong, Y., Hoang, N. T., Lovejoy, A., Stehr, H., Newman, A. M., Gentles, A. J., Kong, W., Truong, D., Martin, S., Chaudhuri, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0127 · Cited by 345
Integral role of Noxa in p53-mediated apoptotic response
Shibue, T., Takeda, K., Oda, E., Tanaka, H., Murasawa, H., Takaoka, A., Morishita, Y., Akira, S., Taniguchi, T., & Tanaka, N. (2003) · Genes & Development · doi:10.1101/gad.1103603 · Cited by 338
Michael, A. (1887) · Journal für Praktische Chemie · doi:10.1002/prac.18870350136 · Cited by 332
The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death
Banjac, A., Perisic, T., Sato, H., Seiler, A., Bannai, S., Weiss, N., Kölle, P., Tschoep, K., Issels, R. D., Daniel, P. T., et al. (2008) · Oncogene · doi:10.1038/sj.onc.1210796 · Cited by 324
Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation
Liu, D. S., Duong, C. P., Haupt, S., Montgomery, K. G., House, C. M., Azar, W. J., Pearson, H. B., Fisher, O. M., Read, M., Guerra, G. R., et al. (2017) · Nature Communications · doi:10.1038/ncomms14844 · Cited by 321 · cited 19×
“…via MQ, to bind and deplete GSH (Tessoulin et al., 2014; Mohell et al., 2015) and inhibit Grx and Trx (Haffo et al., 2018) will have the same effect on the redox balance, and is consistent with the identification of SLC7A11 as marker for decreased sensitivity to APR-246 (Liu et al., 2017a).”
BackgroundResultSelf-citationRole of Cysteine Residues in Regulation of p53 Function
Rainwater, R., Parks, D., Anderson, M. E., Tegtmeyer, P., & Mann, K. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.7.3892 · Cited by 306
Soussi, T., & Wiman, K. G. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.53 · Cited by 305
Self-citationNQO1 stabilizes p53 through a distinct pathway
Asher, G., Lotem, J., Kama, R., Sachs, L., & Shaul, Y. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052706799 · Cited by 291 · cited 1×
“Studies have shown that NQO1 levels are elevated in cancer compared to healthy tissues (Belinsky and Jaiswal, 1993) and that NQO1 stabilizes wild-type p53, especially under oxidative stress (Asher et al., 2002).”
BackgroundRushworth, S. A., Zaitseva, L., Murray, M. Y., Shah, N. M., Bowles, K. M., & MacEwan, D. J. (2012) · Blood · doi:10.1182/blood-2012-04-422121 · Cited by 290
NAD(P)H:Quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues
Belinsky, M., & Jaiswal, A. K. (1993) · Cancer and Metastasis Reviews · doi:10.1007/bf00689804 · Cited by 269
APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
Zhang, Q., Bykov, V. J. N., Wiman, K. G., & Zawacka-Pankau, J. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0463-7 · Cited by 261
Self-citationPRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252 · cited 1×
“In agreement with this idea, APR-246 has been shown to synergize with chemotherapeutic drugs such as adriamycin and cisplatin (Bykov et al., 2005; Mohell et al., 2015).”
BackgroundSelf-citationTrxR1 as a Potent Regulator of the Nrf2-Keap1 Response System
Cebula, M., Schmidt, E. E., & Arnér, E. S. J. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6378 · Cited by 250
Walerych, D., Lisek, K., Sommaggio, R., Piazza, S., Ciani, Y., Dalla, E., Rajkowska, K., Gaweda-Walerych, K., Ingallina, E., Tonelli, C., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3380 · Cited by 239 · cited 5×
“Interestingly, and as will be discussed further below, mutant p53 has been shown to bind Nrf2 and modulate its transactivation capacity (Walerych et al., 2016; Liu et al., 2017a; Lisek et al., 2018).”
BackgroundInfluentialFoxM1, a critical regulator of oxidative stress during oncogenesis
Park, H. J., Carr, J. R., Wang, Z., Nogueira, V., Hay, N., Tyner, A. L., Lau, L. F., Costa, R. H., & Raychaudhuri, P. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.239 · Cited by 235
Linehan, W. M., & Rouault, T. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0304 · Cited by 223
Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53
Wassman, C. D., Baronio, R., Demir, Ö., Wallentine, B. D., Chen, C.-K., Hall, L. V., Salehi, F., Lin, D.-W., Chung, B. P., Wesley Hatfield, G., et al. (2013) · Nature Communications · doi:10.1038/ncomms2361 · Cited by 223
Biological functions of p53 isoforms through evolution: lessons from animal and cellular models
Marcel, V, Dichtel-Danjoy, M.-L., Sagne, C., Hafsi, H., Ma, D., Ortiz-Cuaran, S., Olivier, M., Hall, J., Mollereau, B., Hainaut, P., et al. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.120 · Cited by 210
Diverse Functional Roles of Reactive Cysteines
Pace, N. J., & Weerapana, E. (2013) · ACS Chemical Biology · doi:10.1021/cb3005269 · Cited by 204
Nrf2-ARE pathway regulates induction of Sestrin-2 expression
Shin, B. Y., Jin, S. H., Cho, I. J., & Ki, S. H. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.06.026 · Cited by 202
Velu, C. S., Niture, S. K., Doneanu, C. E., Pattabiraman, N., & Srivenugopal, K. S. (2007) · Biochemistry · doi:10.1021/bi700425y · Cited by 201
Shi, Y., Ghosh, M., Kovtunovych, G., Crooks, D. R., & Rouault, T. A. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.11.002 · Cited by 194
Ge, W., Zhao, K., Wang, X., Li, H., Yu, M., He, M., Xue, X., Zhu, Y., Zhang, C., Cheng, Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.008 · Cited by 188
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Mohell, N., Alfredsson, J., Fransson, Å., Uustalu, M., Byström, S., Gullbo, J., Hallberg, A., Bykov, V. J. N., Björklund, U., & Wiman, K. G. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.143 · Cited by 183
Self-citationZinc Binding and Redox Control of p53 Structure and Function
Hainaut, P., & Mann, K. (2001) · Antioxidants & Redox Signaling · doi:10.1089/15230860152542961 · Cited by 182
Kinetics of p53 Binding to Promoter Sites In Vivo
Szak, S. T., Mays, D., & Pietenpol, J. A. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.10.3375-3386.2001 · Cited by 179
Peng, X., Zhang, M.-Q.-Z., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J. N., Arnér, E. S. J., & Wiman, K. G. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.417 · Cited by 170
Self-citationPRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance
Tessoulin, B., Descamps, G., Moreau, P., Maïga, S., Lodé, L., Godon, C., Marionneau-Lambot, S., Oullier, T., Le Gouill, S., Amiot, M., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548800 · Cited by 166
Thioredoxin-related protein of 14 kDa is an efficient L-cystine reductase and S-denitrosylase
Pader, I., Sengupta, R., Cebula, M., Xu, J., Lundberg, J. O., Holmgren, A., Johansson, K., & Arnér, E. S. J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317320111 · Cited by 166
Redox signalling and transition metals in the control of the p53 pathway
Méplan, C., Richard, M.-J., & Hainaut, P. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00297-x · Cited by 166
Andrysik, Z., Galbraith, M. D., Guarnieri, A. L., Zaccara, S., Sullivan, K. D., Pandey, A., MacBeth, M., Inga, A., & Espinosa, J. M. (2017) · Genome Research · doi:10.1101/gr.220533.117 · Cited by 154
Tumor Protein 53–Induced Nuclear Protein 1 Is a Major Mediator of p53 Antioxidant Function
Cano, C. E., Gommeaux, J., Pietri, S., Culcasi, M., Garcia, S., Seux, M., Barelier, S., Vasseur, S., Spoto, R. P., Pébusque, M.-J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2320 · Cited by 151
Ferredoxin reductase is critical for p53-dependent tumor suppression via iron regulatory protein 2
Zhang, Y., Qian, Y., Zhang, J., Yan, W., Jung, Y.-S., Chen, M., Huang, E., Lloyd, K., Duan, Y., Wang, J., et al. (2017) · Genes & Development · doi:10.1101/gad.299388.117 · Cited by 151
p53 and glucose metabolism: an orchestra to be directed in cancer therapy
Gomes, A. S., Ramos, H., Soares, J., & Saraiva, L. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.015 · Cited by 148
A temperature‐sensitive mutant of human p53.
Zhang, W., Guo, X. Y., Hu, G., Liu, W. B., Shay, J. W., & Deisseroth, A. B. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06543.x · Cited by 139
Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2
Tung, M.-C., Lin, P.-L., Wang, Y.-C., He, T.-Y., Lee, M.-C., Yeh, S.-D., Chen, C.-Y., & Lee, H. (2015) · Oncotarget · doi:10.18632/oncotarget.6150 · Cited by 138
Bykov, V. J. N., Zhang, Q., Zhang, M., Ceder, S., Abrahmsen, L., & Wiman, K. G. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00021 · Cited by 137
Self-citationPeng, X., Zhang, M.-Q.-Z., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J., Arnér, E. S., & Wiman, K. G. (2017) · Cell Death & Disease · doi:10.1038/cddis.2016.137 · Cited by 134
Self-citationRoles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity
Seemann, S., & Hainaut, P. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208549 · Cited by 132
TXNIP maintains the hematopoietic cell pool by switching the function of p53 under oxidative stress
Jung, H., Kim, M. J., Kim, D. O., Kim, W. S., Yoon, S.-J., Park, Y.-J., Yoon, S. R., Kim, T.-D., Suh, H.-W., Yun, S., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.06.002 · Cited by 132
Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas
Todoric, J., Antonucci, L., Di Caro, G., Li, N., Wu, X., Lytle, N. K., Dhar, D., Banerjee, S., Fagman, J. B., Browne, C. D., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.011 · Cited by 131
A TIGAR-Regulated Metabolic Pathway Is Critical for Protection of Brain Ischemia
Li, M., Sun, M., Cao, L., Gu, J., Ge, J., Chen, J., Han, R., Qin, Y., Zhou, Z., Ding, Y., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.4655-13.2014 · Cited by 125
NADPH-dependent and -independent disulfide reductase systems
Miller, C. G., Holmgren, A., Arnér, E. S. J., & Schmidt, E. E. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.03.051 · Cited by 118
Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells
Lisek, K., Campaner, E., Ciani, Y., Walerych, D., & Del Sal, G. (2018) · Oncotarget · doi:10.18632/oncotarget.24974 · Cited by 118
2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells
Bauer, M. R., Joerger, A. C., & Fersht, A. R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610421113 · Cited by 117
Cheteh, E. H., Augsten, M., Rundqvist, H., Bianchi, J., Sarne, V., Egevad, L., Bykov, V. J., Östman, A., & Wiman, K. G. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.225 · Cited by 117
Self-citationHe, X., & Ma, Q. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.081133 · Cited by 111
Хромова, Н. В., Kopnin, P., Степанова, Е. В., Agapova, L. S., & Kopnin, B. P. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.10.049 · Cited by 110
Lee, P., Vousden, K. H., & Cheung, E. C. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-1 · Cited by 107
Kalo, E., Kogan-Sakin, I., Solomon, H., Bar-Nathan, E., Shay, M., Shetzer, Y., Dekel, E., Goldfinger, N., Buganim, Y., Stambolsky, P., et al. (2012) · Journal of Cell Science · doi:10.1242/jcs.106815 · Cited by 103
Pearson, G. D., & Merrill, G. F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.10.5431 · Cited by 99
Flatt, P. M., Polyák, K., Tang, L. J., Scatena, C. D., Westfall, M. D., Rubinstein, L. A., Yu, J., Kinzler, K. W., Vogelstein, B., Hill, D. E., et al. (2000) · Cancer Letters · doi:10.1016/s0304-3835(00)00441-9 · Cited by 97
You, A., Nam, C.-W., Wakabayashi, N., Yamamoto, M. P., Kensler, T. W., & Kwak, M.-K. (2011) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.12.034 · Cited by 93
The stress protein TP53INP1 plays a tumor suppressive role by regulating metabolic homeostasis
Saadi, H., Seillier, M., & Carrier, A. (2015) · Biochimie · doi:10.1016/j.biochi.2015.07.024 · Cited by 79
Casso, D. J., & Beach, D. (1996) · Molecular and General Genetics MGG · doi:10.1007/s004380050259 · Cited by 78
Domenico, F. D., Cenini, G., Sultana, R., Perluigi, M., Uberti, D., Memo, M., & Butterfield, D. A. (2009) · Neurochemical Research · doi:10.1007/s11064-009-9924-9 · Cited by 77
Tran, T. Q., Lowman, X. H., Reid, M. A., Mendez-Dorantes, C., Pan, M., Yang, Y., & Kong, M. (2017) · Oncogene · doi:10.1038/onc.2016.360 · Cited by 76
Haffo, L., Lu, J., Bykov, V. J. N., Martin, S. S., Ren, X., Coppo, L., Wiman, K. G., & Holmgren, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-31048-7 · Cited by 73 · cited 3×
“The ability of APR-246, via MQ, to bind and deplete GSH (Tessoulin et al., 2014; Mohell et al., 2015) and inhibit Grx and Trx (Haffo et al., 2018) will have the same effect on the redox balance, and is consistent with the identification of SLC7A11 as marker for decreased sensitivity to APR-246 (Liu et al., 2017a).”
BackgroundResultSelf-citationThioredoxins function as deglutathionylase enzymes in the yeast Saccharomyces cerevisiae
Greetham, D., Vickerstaff, J., Shenton, D., Perrone, G. G., Dawes, I. W., & Grant, C. M. (2010) · BMC Biochemistry · doi:10.1186/1471-2091-11-3 · Cited by 72
Asher, G., Lotem, J., Tsvetkov, P., Reiss, V., Sachs, L., & Shaul, Y. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2436329100 · Cited by 70
Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding
Kaar, J. L., Basse, N., Joerger, A. C., Stephens, E., Rutherford, T. J., & Fersht, A. R. (2010) · Protein Science · doi:10.1002/pro.507 · Cited by 67
Thiosemicarbazones Functioning as Zinc Metallochaperones to Reactivate Mutant p53
Yu, X., Blanden, A., Tsang, A. T., Zaman, S., Liu, Y., Gilleran, J., Bencivenga, A. F., Kimball, S. D., Loh, S. N., & Carpizo, D. R. (2017) · Molecular Pharmacology · doi:10.1124/mol.116.107409 · Cited by 64
Tanaka, N., Zhao, M., Tang, L., Patel, A. A., Xi, Q., Van, H. T., Takahashi, H., Osman, A. A., Zhang, J., Wang, J., et al. (2018) · Oncogene · doi:10.1038/s41388-017-0032-z · Cited by 57
Kallin, A., Johannessen, L. E., Cani, P. D., Marbehant, C. Y., Essaghir, A., Foufelle, F., Ferré, P., Heldin, C.-H., Delzenne, N. M., & Demoulin, J.-B. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700136-jlr200 · Cited by 53
Madan, E., Gogna, R., Kuppusamy, P., Bhatt, M. L. B., Mahdi, A. A., & Pati, U. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.06798-11 · Cited by 53
Wang, R., Yin, C., Li, X., Yang, X.-Z., Yang, Y., Zhang, M.-Y., Wang, H., & Zheng, X. (2016) · Aging · doi:10.18632/aging.100967 · Cited by 53
Scotcher, J., Clarke, D. J., Weidt, S. K., Mackay, C. L., Hupp, T. R., Sadler, P. J., & Langridge-Smith, P. R. R. (2011) · Journal of the American Society for Mass Spectrometry · doi:10.1007/s13361-011-0088-x · Cited by 51
p53 dynamics orchestrates with binding affinity to target genes for cell fate decision
Wu, M., Ye, H., Tang, Z., Shao, C., Lu, G., Chen, B., Yang, Y., Wang, G., & Hao, H. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.492 · Cited by 49
Mutant p53 rescue and modulation of p53 redox state
Bykov, V. J. N., Lambert, J. M. R., Hainaut, P., & Wiman, K. G. (2009) · Cell Cycle · doi:10.4161/cc.8.16.9382 · Cited by 46
Self-citationYusuf, M. A., Chuang, T. L., Bhat, G. J., & Srivenugopal, K. S. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.06.020 · Cited by 46
Liu, K., Chen, W., Lei, S., Xiong, L., Zhao, H., Dong, L., Lei, Z., Zhou, N., Yao, H., & Liang, Y. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.477 · Cited by 42
Yu, X., Kogan, S., Chen, Y., Tsang, A. T., Withers, T., Lin, H., Gilleran, J., Buckley, B., Moore, D., Bertino, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0822 · Cited by 42
TXNIP interacts with hEcd to increase p53 stability and activity
Suh, H., Yun, S., Song, H., Jung, H., Park, Y.-J., Kim, T., Yoon, S. R., & Choi, I. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.07.036 · Cited by 23
Jana, S., Patra, K., Jana, J., Mandal, D. P., & Bhattacharjee, S. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.02.030 · Cited by 23
Role of Thiol Reactivity for Targeting Mutant p53
Zhang, Q., Bergman, J., Wiman, K. G., & Bykov, V. J. N. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.06.013 · Cited by 20
Self-citationIntegrative omics analysis of p53‐dependent regulation of metabolism
Huang, J., Long, Z., Lin, W., Liao, X., Xie, Y., Liu, L., & Ma, W. (2018) · FEBS Letters · doi:10.1002/1873-3468.12968 · Cited by 18
Cited by
Targeting ROS in cancer: rationale and strategies
Glorieux, C., Liu, S., Trachootham, D., & Huang, P. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00979-4 · Cited by 651
“By contrast, BCL-2, a mitochondrial membrane-associated protein, exerts its non-canonical antioxidant function to help maintain redox homeostasis. c , ROS generated in the tumour microenvironment through various mechanisms, including aberrant metabolism due to dysfunctional mitochondria, toll-like receptor (TLR) activ…”
InfluentialLacroix, M., Riscal, R., Arena, G., Linares, L. K., & Le Cam, L. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.10.002 · Cited by 373
The complexity of p53-mediated metabolic regulation in tumor suppression
Liu, Y., & Gu, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.010 · Cited by 261
DNA damage and oxidant stress activate p53 through differential upstream signaling pathways
Shi, T., van Soest, D. M. K., Polderman, P. E., Burgering, B. M. T., & Dansen, T. B. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.06.013 · Cited by 172
Roles of reactive oxygen species in inflammation and cancer
Yu, Y., Liu, S., Yang, L., Song, P., Liu, Z., Liu, X., Yan, X., & Dong, Q. (2024) · MedComm · doi:10.1002/mco2.519 · Cited by 164
Metadata
- Authors
- Eriksson, S. E., Ceder, S., Bykov, V. J. N., & Wiman, K. G.
- Affiliations
- Karolinska Institutet (SE)
- Corresponding author
- Wiman, Klas G
- Venue
- Journal of Molecular Cell Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-02-14
- Volume
- 11
- Issue
- 4
- Pages
- 330-341
- ISSN
- 1674-2788 (ISSN-L)
- 1759-4685
- PMC
- PMC6734141
- OpenAlex
- W2911745809
- Cited by
- 123
- References
- 132
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 19 · 2023: 18 · 2022: 15 · 2021: 20 · 2020: 13 · 2019: 8
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Molecular Cell Biology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Swedish Medical Research Council
- Swedish Cancer Fund
- Swedish Childhood Cancer Fund
- Radiumhemmets Forskningsfonder
- Knut & Alice Wallenberg Foundation
- European Research Council
- Aprea Therapeutics AB
- Karolinska Institutet
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Keywords
- TP53, p53, cellular redox homeostasis, TP53 mutation, missense mutations, Nrf2, TIGAR, GLS2, zinc binding, glutathione, cancer therapy, transcriptional regulation
- MeSH terms
- Antioxidants, DNA, Humans, Neoplasms, Sulfhydryl Compounds, Tumor Suppressor Protein p53, Oxidative Stress, Mutation, Missense, Small Molecule Libraries, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.